维升药业红筹架构及高管员工持股分析

恒杉咨询
Jul 02, 2025

2025年3月21日,聚焦内分泌疾病治疗的创新药企业——维升药业(Visen Pharmaceuticals)正式登陆港交所,成为医疗健康领域又一标志性红筹上市案例。这家专注于内分泌治疗的生物医药企业,不仅逆势完成IPO,更通过一套典型的红筹架构,跑通了医疗健康企业出海资本市场的标准路径。一、红筹架构搭建1.1 红筹架构搭建背景红筹架构是指中国境内的公司(不包含港澳台)在境外设立离岸公司,然后将...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10